Investigation of the molecular pathogenesis of cardiac amyloidosis using 18F-flutemetamol and 11C-PiB PET/CT and 99mTc-HMDP scintigraphy.

Investigation of the molecular pathogenesis of cardiac amyloidosis using 18F-flutemetamol and 11C-PiB PET/CT and 99mTc-HMDP scintigraphy. - FMM, PiB, and HMDP accumulation in cardiac amyloidosis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000054523

Enrollment

Registered

2024-05-31

Start date

2023-09-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiac amyloidosis

Interventions

One PET scan for 18F-flutemetamol and 11C-PiB, and one 99mTc-HMDP scintigraphy will be performed on eligible patients. The order of each imaging examination is unequal, and although no interval betwe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with or suspected of having cardiac amyloidosis

Exclusion criteria

Exclusion criteria: Patients who are or may be pregnant Patients with an immediate and obvious life-threatening condition Other patients deemed inappropriate by the investigator

Design outcomes

Primary

Measure	Time frame
18F-flutemetamol PET/CT accumulation pattern or absence of accumulation in cardiac amyloidosis	—

Secondary

Measure	Time frame
Differences between 18F-flutemetamol PET/CT and 11C-PiB PET/CT and 99mTc-HMDP scintigraphy in cardiac amyloidosis according to degree of accumulation and clinical severity	—

Countries

Japan

Contacts

Public ContactNorikane Takashi

Kabawa University Department of Radiology

radiol-m@kagawa-u.ac.jp087-898-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026